Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.

Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaax0720. doi: 10.1126/scitranslmed.aax0720.

PMID:
31578241
2.

Local gene delivery of heme oxygenase-1 by adeno-associated virus into osteoarthritic mouse joints exhibiting synovial oxidative stress.

Kyostio-Moore S, Bangari DS, Ewing P, Nambiar B, Berthelette P, Sookdeo C, Hutto E, Moran N, Sullivan J, Matthews GL, Scaria A, Armentano D.

Osteoarthritis Cartilage. 2013 Feb;21(2):358-67. doi: 10.1016/j.joca.2012.11.002. Epub 2012 Nov 11.

3.

STR/ort mice, a model for spontaneous osteoarthritis, exhibit elevated levels of both local and systemic inflammatory markers.

Kyostio-Moore S, Nambiar B, Hutto E, Ewing PJ, Piraino S, Berthelette P, Sookdeo C, Matthews G, Armentano D.

Comp Med. 2011 Aug;61(4):346-55.

4.

Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.

Rouleau C, Smale R, Fu YS, Hui G, Wang F, Hutto E, Fogle R, Jones CM, Krumbholz R, Roth S, Curiel M, Ren Y, Bagley RG, Wallar G, Miller G, Schmid S, Horten B, Teicher BA.

Int J Oncol. 2011 Jul;39(1):73-89. doi: 10.3892/ijo.2011.1020. Epub 2011 Apr 29.

PMID:
21537839
5.

Identification of the chondrocyte lineage using microfibril-associated glycoprotein-2, a novel marker that distinguishes chondrocytes from synovial cells.

Rapko S, Zhang M, Richards B, Hutto E, Dethlefsen S, Duguay S.

Tissue Eng Part C Methods. 2010 Dec;16(6):1367-75. doi: 10.1089/ten.TEC.2009.0772. Epub 2010 May 10.

6.

Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.

Marshall J, McEachern KA, Chuang WL, Hutto E, Siegel CS, Shayman JA, Grabowski GA, Scheule RK, Copeland DP, Cheng SH.

J Inherit Metab Dis. 2010 Jun;33(3):281-9. doi: 10.1007/s10545-010-9072-z. Epub 2010 Mar 25.

7.

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM.

Immunology. 2009 Oct;128(2):260-70. doi: 10.1111/j.1365-2567.2009.03115.x.

8.

A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.

McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J.

Mol Genet Metab. 2007 Jul;91(3):259-67. Epub 2007 May 16.

PMID:
17509920
9.

AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.

McEachern KA, Nietupski JB, Chuang WL, Armentano D, Johnson J, Hutto E, Grabowski GA, Cheng SH, Marshall J.

J Gene Med. 2006 Jun;8(6):719-29.

PMID:
16528760
10.
11.

The treatment of superficial fungus infections of the skin with oral griseofulvin.

CALLAWAY JL, NEWTON G, GISLERUD G, HUTTO E, MARASCALCO J, BLAYLOCK K.

N C Med J. 1960 Mar;21:109-11. No abstract available.

PMID:
13806988

Supplemental Content

Support Center